TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02171143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV)
Study: NCT02623205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
Study: NCT01569815
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400 mg once daily
Study: NCT02269696
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal of volume compared to metoprolol.
Study: NCT02361645
Drug: Ketorolac 0.5% eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02116842
Drug: 40 µg fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given with different doses of bupivacaine in epidural block.
Study: NCT01890265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT00360178
Drug: Valsartan plus Hydrochlorothiazide
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00360178
Drug: Candesartan plus Hydrochlorothiazide
Normalized name: candesartan / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04162470
Drug: REGN3918
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) every week (QW) over the treatment period
Study: NCT04178187
Drug: Caps Lactolevure
Normalized name: silica, trimethylsilyl capped
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
Study: NCT04178187
Drug: Caps Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caps Placebo
Study: NCT02361645
Drug: Indomethacin 0.5% eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361645
Drug: Bromfenac 0.09% eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361645
Drug: Nepafenac 0.1% eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03360760
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Study: NCT03360760
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
Study: NCT00977886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 10 days
Study: NCT00977886
Drug: ELB353
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 10 days
Study: NCT01541488
Drug: Placebo to BI 1021958
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
Study: NCT02772978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
Study: NCT00046553
Drug: RU-486 (Mifepristone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02071888
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutaminase inhibitor
Study: NCT01997515
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (placebo) will receive the same amount of saline.
Study: NCT03647228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator calculated volume to match active comparator inhaled or nebulized.
Study: NCT03464526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily, oral
Study: NCT03616899
Drug: KPI-121 Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPI-121 Ophthalmic Suspension
Study: NCT03616899
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle for KPI-121 0.25% ophthalmic suspension
Study: NCT01983358
Drug: JPI-289
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP-1 inhibitor
Study: NCT00939913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
Study: NCT01053507
Drug: sumatriptan/naproxen sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Study: NCT01053507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Study: NCT01047007
Drug: 5-FU 1000 mg/m^2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
Study: NCT00429143
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
Study: NCT00976144
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
Study: NCT01989221
Drug: Sancuso®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
Study: NCT00059202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Urso
Study: NCT02664116
Drug: Diclofenac postassium powder for oral solution and placebo injection
Normalized name: diclofenac Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
Study: NCT02664116
Drug: Ketorolac intramuscular injection and placebo oral solution
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
Study: NCT01201928
Drug: Comparator administered in parent trial
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
Study: NCT01201928
Drug: Technosphere Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
Study: NCT02955888
Drug: PBI4050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT02955888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT03886948
Drug: LY3074828
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT01290926
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 600mg/day capecitabine 1250 mg/m²/day
Study: NCT01125410
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vaginal cream, 2%, once daily for 7 days
Study: NCT00566046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
Study: NCT03084029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 international units
Study: NCT00786487
Drug: 20% lipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml/min for 6 hours
Study: NCT03877289
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin.
Study: NCT04396990
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study: NCT04396990
Drug: Topical Prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care topical drop treatment
Study: NCT04611750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given for 14 days
Study: NCT01466348
Drug: Paracetamol and Caffeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg and caffeine 130 mg
Study: NCT02647086
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytochrome P450 substrate
Study: NCT00049101
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00049101
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01791842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00183092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg by mouth three times a day
Study: NCT00966602
Drug: VX-809 & VX-770
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
Study: NCT00966602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03676322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to M5049.
Study: NCT01995084
Drug: [F-18]HX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Study: NCT00878007
Drug: Intermittent screening and treatment for malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
Study: NCT00605475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
Study: NCT02717988
Drug: SKI-O-703 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient
Study: NCT02717988
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 180 mg capsule filled with microcrystalline cellulose
Study: NCT04311112
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00094926
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo IM injections every 2wks for 52wks
Study: NCT04713410
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Study: NCT03033680
Drug: [F-18]PBR06
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiopharmaceutical
Study: NCT02357901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
Study: NCT04206631
Drug: Doxycycline Capsule
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
Study: NCT03774771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT00074139
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00074139
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03125980
Drug: capecitabine plus oxaliplatin before and after surgery
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)
Study: NCT00769288
Drug: 2'-F-ara-deoxyuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00400400
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
Study: NCT02871349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
Study: NCT04069312
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
Study: NCT04199585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, single dose, orally
Study: NCT00196677
Drug: Vitamins, minerals and medical herbs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01154491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
Study: NCT01694433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g daily BID
Study: NCT03071861
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of normal saline, IV, given at less than 24 hours of age
Study: NCT03771040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215057
Drug: topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical anesthetic drops and Group 2
Study: NCT00344175
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02186782
Drug: Clomiphene citrate and Estradiol
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
Study: NCT02737319
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg of rosuvastatin before angioplasty
Study: NCT00400400
Drug: Placebo to mycophenolate sodium
Normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to mycophenolate sodium matching tablets.
Study: NCT00838058
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 250mg tablet, once in the morning in fasted state
Study: NCT00838058
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x250 mg tablets, once in the morning, in fasted state
Study: NCT00838058
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x250mg tablets, once in the morning, in fasted state
Study: NCT00838058
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x250mg tab, once in the morning, after being fed a high fat meal
Study: NCT00838058
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Study: NCT00838058
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x125 mg IR once in the morning after being fed a high fat meal
Study: NCT03371199
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch tablets
Study: NCT00838058
Drug: CE 224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
Study: NCT00838058
Drug: CE 224,535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
Study: NCT00400400
Drug: Placebo to mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to mycophenolate mofetil matching capsules.
Study: NCT01497977
Drug: phytoestrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
Study: NCT00869635
Drug: S-1 Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
Study: NCT04461015
Drug: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
Study: NCT04461015
Drug: 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
Study: NCT03001661
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
Study: NCT00413660
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 blinded tablets administered BID
Study: NCT01984775
Drug: GSK2894512 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
Study: NCT01984775
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream does not contain any active pharmaceutical ingredient.
Study: NCT00413660
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01458301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Study: NCT03854617
Drug: Oral NVB Metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
Study: NCT02229786
Drug: Buscopan® plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229786
Drug: Buscopan®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03369665
Drug: Mavenclad®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
Study: NCT01664247
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered s.c. (under the skin) once daily. Dose individually adjusted.
Study: NCT01349205
Drug: Caffeine and sodium Benzoate 10 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, 10mg/kg, IVP, 1 time
Study: NCT01349205
Drug: Caffeine and Sodium Benzoate 20 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, 20 mg/kg, IVP, 1 time
Study: NCT01349205
Drug: 0.9 NS Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, 0-10 ml, IVP, 1 time
Study: NCT03369015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.